Since its establishment in 1998, Seattle Genetics has continuously focused on the human antibodies. The company has been carrying out studies, manipulation, and packaging of drugs ever since. The company through therapies have been able to use their antibodies in destroying cancer cells. This strategy has enabled Seattle Genetics to grow into one of the leading pharmaceutical companies in the Seattle Biotech industry.
Seattle Genetics is the most substantial biotech company in Washington with over 900 employees and a market value of approximately $10 billion. The company is converging on transforming into a big pharmaceutical and has invested enormously on research and marketing. The biotech company’s leading drug, Adcetris treats Hodgkin lymphoma. Hodgkin lymphoma is cancer that affects the lymph system and also spreads to other organs of the body. The drugs positive, expansive tests will lead to an increase of its sales.
The company is going global and is currently providing many products. It has many drugs in its pipeline. According to Clay Siegall, the President, and CEO, Seattle Genetics is looking forward to becoming a big company, and it will not be sold to a big company as most of the biotech companies do. The company is also focusing on managing the complexities of marketing its new drugs globally.
Seattle Genetics is constantly growing and developing. Its stock worth has tripled in the last five years. Its approximation has also been enhanced by higher than 50% in the past year. The rising valuation is a clear indicator that business is booming in the facility. The company has mainly specialized in the production of antibody-drug conjugate (ADC) types of drugs. The drugs which target antigens attach to the outer sides of cancer cells thereby depositing toxin into the cells and killing them. According to Seagull, four out of their eleven drugs will have higher sales in the near future.
Clay Siegall is the Chief Executive Officer of Seattle Genetics. He is also the president of the biotech firm and the Chairman of its Board of Directors. Dr. Clay Siegall founded the company in 1998. He was inspired to establish the company because of his interests in medicine coupled with technology in fighting diseases.
Clay holds a Bachelor’s degree in Zoology from the University of Maryland. He acquired his Ph.D. in Genetics from the George Washington University. Prior to co-founding Seattle Genetics, Clay served in various companies. He was an employee at the National Cancer Institute as well as at the Bristol-Myers Squibb Pharmaceutical Research Institute.
Tempus is a startup that is mobilizing human and monetary resources to fight cancer. Much of the operations at the company include generation and dissemination of useful data to medical professionals. This data will help create a better understanding of the relationship an individual’s genetic makeup and how they respond to different cancer therapies.
Recently, the startup announced that it had joined hands with the University of Chicago Medicine. The partnership involves Tempus availing research data from 1,000 cancer patients to the medical professionals at the institution. The data will include phenotypic, therapeutic and genomic sequences of the patients. This data will be used to establish patterns that could provide alternative therapies in dealing with cancer. With such crucial data, medical professionals can also forecast a patient’s response to various cancer medications. The long-term goal of this project is that eventually, doctors might be able to design custom cancer therapies to each patient that are more targeting and less invasive. Eric Lefkofsky on twitter.
According to a leading medical professional from the University of Chicago, Dr. OlufunmilayoOlopade, the amount of data that is available in patients with breast cancer is alarmingly low despite the fact that breast cancer is one of the most common types of cancer. This reality paints a picture of a sector that is working without sufficient information putting physicians in a hard place when they have to do prescriptions without much guidance.
The University of Chicago is just but one of the many partnerships that Tempus has entered into recently with the aim of advancing the fight against cancer.
Tempus was founded by acclaimed entrepreneur Eric Lefkofsky, who is an alumnus of the University of Michigan. He earned a Bachelor of Laws Degree from the institution. Since then he has been the face of an array of successful ventures including Groupon, Uptake, and Lightbank.
Mr. Lefkofsky has also been successful in philanthropy. He runs the Lefkofsky Family Foundation that began its operations in the year 2006. The foundations work to provide effective programs and initiatives in different sectors. The organization ensures that the vulnerable have access to education, their rights are protected, and medical innovations change the field of medicine.
Eric Lefkofsky is an American entrepreneur who was born in Detroit, Michigan. He was born in September of 1969 to his dad who was a structural engineer and his mom who was a school teacher. He is currently the chairman of Groupon and also the co-founder and CEO of Tempus.Eric Lefkofsky grew up in the Southfield, Michigan area. He attended the local schools and graduated from the Southfield-Lathrup high school in 1987. After attending the local high school Lefkofsky then went on to attend the University of Michigan. He graduated in 1991 with high honors before moving on to continue his education.
After graduating from the University of Michigan in 1991 Eric Lefkofsky then went on to attend the University of Michigan Law School located in Ann Arbor, Michigan. The law school was founded in 1859 and is one of the top law schools in the U.S. He eventually graduated receiving his Juris doctor in 1993.Upon completing his education at the University of Michigan law school Eric Lefkofsky went on to work for a variety of different companies. He is currently the chairman as well as the co-founder of the e-commerce website Groupon. He is also the co-founder and CEO of Tempus which is a new and innovative way to treat cancer patients.
In 2001 Lefkofsky co-founded Innerworkings. Innerworkings is a marketing firm that currently serves a variety of top Fortune 500 brands in a wide range of industries. The company is currently headquartered out of Chicago, Illinois and currently employs over 1,500 employees.Eric Lefkofsky also co-founded Echo Global Logistics in 2005. It is a freight logistics company that is currently headquartered out of Chicago, Illinois. Eric Lefkofsky also co-founded Mediaocean. Mediaocean was first founded in 2012 and is an advertising firm that currently has over 800 employees.
These are just a few of the many different companies that Eric Lefkofsky has worked for or co-founded. He is also involved in many different philanthropic endeavors including The Giving Pledge as well as his own foundation The Lefkofsky Foundation which he started back in 2006 with his wife Elizabeth. It focuses on changing the lives and direction of children. It has currently helpful fund more than 50 different organizations all around the world.
Cancer has continued to have an adverse effect on many families. According to official data, cancer cases continue to increase. In addition, therapies/ treatment for the disease remain elusive. However, some experts have been conducting in depth research on how to develop viable cancer drugs. One of these researchers is Clay Siegall, a genetic expert. For the better part of his career, Siegall has been developing cancer therapies.
In 1997, Siegall founded Seattle Genetics. The scientist is the CEO of the corporation. Over the years, he has been using his experience to find a drug that cure or improve the lives of cancer patients. Clay has been a proponent of the antibody-drug conjugates (ADCs) technology. The company’s stock prices rose by more than 300 percent in five years owing to the success of this method.
Siegall has had an impressive career. He has worked for some of the best research institutions and pharmaceutical companies in the United States. They include Bristol-Myers Squibb Pharmaceutical Research Institute and National Cancer Institute. In the former company, he worked as a senior research investigator. In the latter, Clay worked as a Staff Fellow and Biotechnology Fellow. Clay holds a doctorate degree in genetics from the George Washington University.
Seattle Genetics has greatly benefited from the visionary leadership of Dr. Siegall. He has been seeking funds for the company, a move that has enabled it to raise adequate funds for its operations and development of cancer therapies. Clay played an instrumental role in commercializing its first ADCs therapy. The drug, ADCETRIS, is sold in over 60 countries. FDA approved it in 2011. Seattle Genetics has also been able to generate revenues from licensing its technology to other companies that engage in developing cancer therapies. In total, Clay has helped the company to generate more than $1.2 billion in funding.
Siegall is not slowing down. The scientist continues to research heavily on cancer therapies. His hard work has helped him to make new discoveries about cancer. Clay has 15 patents. Dr. Siegall is also the author of several scientific papers, which are published by various medical journals. He has at least 70 peer-reviewed publications. Recently, the Alumnus of University of Maryland honored the scientist for his contribution to cancer and cancer therapy research.